Register or Submit a manuscript.

Table of Contents

Open Access

ISSN 2577-5820

© 2022 by the authors; CC BY 4.0 licence

OBM Transplantation , Volume 6 , Issue 3 (2022)

Pages: 84

Published: December 2022

(This book is a printed edition that was published in OBM Transplantation)

Download PDF

Order Print Version
Price: 28.99 USD
Format: Soft Cover
Quantity:

Cover story: Successfully transplanting cells and organs from a donor into an immunologically disparate recipient is one of the greatest treatment advances in the history of medicine. Immunosuppression before and after allogeneic transplant has been found to dramatically improve allograft survival and, despite side effects, has been a mainstay of patient management. View this paper.

Volume 6,Issue 3

Open Access Original Research

The P2X7 Receptor Antagonist AZ10606120 Does Not Alter Graft-Versus-Host Disease Development and Increases Serum Human Interferon-γ in a Humanized Mouse Model

Received: 06 June 2022;  Published: 06 September 2022;  doi: 10.21926/obm.transplant.2203166

Abstract

Allogeneic hematopoietic stem cell transplantation is a curative therapy for hematological malignancies, but its efficacy is limited by graft-versus-host disease (GVHD). This life-threatening disorder develops when donor (graft) immune cells cause inflammatory damage to recipient (host) tissues. The immune cell receptor channel P2X7 and its ligand adenosine 5’-triphosphate (ATP) have been implicated in GVHD pathogenesis. Therefore, this signaling axis represents a potential therapeutic target. T [...]

Open Access Short Communication

Promising Tactics with Certain Probiotics for the Treatment of Nephropathy in Hematopoietic Stem Cell Transplantation

Received: 02 May 2022;  Published: 30 August 2022;  doi: 10.21926/obm.transplant.2203165

Abstract

Hematopoietic stem cell transplantation (HSCT) is a standard form of cellular therapy for patients suffering from malignant hematological diseases. However, graft-versus-host disease (GVHD) is a very serious complication and a major cause of morbidity and mortality after allogeneic HSCT. Calcineurin inhibitors, such as cyclosporine, are widely used to enhance the survival of patients who have undergone HSCT. Unfortunately, both GVHD and cyclosporine occasionally cause nephropathy. Several studie [...]

Open Access Case Report

Bilateral Corneal Perforation in a Patient with Chronic Ocular Graft-Versus-Host Disease: A Case Report and Literature Review

Received: 17 June 2022;  Published: 02 August 2022;  doi: 10.21926/obm.transplant.2203164

Abstract

Graft-versus-host disease (GVHD) is a serious complication that may occur in patients receiving allogeneic hematopoietic stem cell transplant (HSCT). GVHD occurs because of the immunological reaction between the donor’s T cells and the recipient’s antigens; GVHD may develop in different tissues, including the eye. Corneal perforation is an uncommon but vision-threatening manifestation of GVHD. We reported the case of a 65-year-old male patient who developed corneal p [...]

Open Access Editorial

The Role of Cytochrome P450 2J2 in Cancer: Cell Protector, Therapeutic Target, or Prognostic Marker?

Received: 08 July 2022;  Published: 27 July 2022;  doi: 10.21926/obm.transplant.2203163

Abstract

Cytochrome P450 2J2 (CYP2J2) is one of the recently discovered enzymes that is involved in the metabolism of several drugs. It is mainly an extrahepatic enzyme which can, to some extent, explain some the drugs’ side effects such as cyclophosphamide (Cy). Cyclophosphamide is an alkylating agent that is commonly used in conditioning prior to stem cell transplantation. It is a prodrug that is bio-activated by several CYPs including CYP2J2. Cy is known to have several side effects and its extrahepat [...]

Open Access Review

Antibody-Based Preparative Regimens for Cell, Tissue and Organ Transplantation

Received: 24 November 2021;  Published: 08 July 2022;  doi: 10.21926/obm.transplant.2203162

Abstract

The ability to successfully transplant cells and organs from a donor into an immunologically disparate recipient is one of the greatest treatment advances in the history of medicine. Nevertheless, acute and chronic rejection, graft versus host disease, and the inability to identify suitable donors continue to be challenges and limit broader application of cell and organ transplantation to the many patients that could benefit. Immunosuppression before and after allogeneic transplant has been foun [...]

Open Access Interview

An Interview with Prof. Luca Brazzi

Received: 01 July 2022;  Published: 03 July 2022;  doi: 10.21926/obm.transplant.2203161
Newsletter  

TOP